Medical Advocates
Cryptococcosis
  Drugs

 Aceyazolamide       Azoles: General Reports
Albaconazole          Antifungals: General Reports
Amphotericin B       Antiretrovirals: General Reports         
Fluconazole
Flucytosine
 IFN-gamma  
HAART/ART
 IL-12   
 Isavuconazole
 Itraconazole
 Posaconazole
 Saquinavir
 Voriconazole   
Cryptococcosis Main Page Main New/Noteworthy Home Page 
Last Update:  July 06, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
Aceyazolamide
       

     Journal Papers, Abstracts, and Commentaries

  A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment
of elevated intracranial pressure in cryptococcal meningitis.
Newton PN, Thai le H, Tip NQ
Clin Infect Dis 2002 Sep 15;35(6):769-72
 Abstract		  
Albaconazole
       

        Journal Papers, Abstracts, and Commentaries

  In Vitro and In Vivo Efficacies of the New Triazole Albaconazole against Cryptococcus
neoformans.
Miller JL, Schell WA, Wills EA, et al  
Antimicrob Agents Chemother. 2004 Feb;48(2):384-7.
Abstract
Amphotericin B
       

        Journal Papers, Abstracts, and Commentaries

 
High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in
HIV-infected patients: a randomized trial.
Bicanic T, Wood R, Meintjes G, et al  
Clin Infect Dis. 2008 Jul 1;47(1):131-2.
 Abstract
 
Emergence of Amphotericin B-Resistant Cryptococcus laurentii Meningoencephalitis
Shortly After Treatment for Cryptococcus neoformans Meningitis in a Patient with AIDS.
Manfredi R, Fulgaro C, Sabbatani S, et al
AIDS Patient Care STDS. 2006 Apr;20(4):227-32.
 Abstract
 
Efficacy of Amphotericin B in Combination with Flucytosine against Flucytosine-Susceptible
or Flucytosine-Resistant Isolates of Cryptococcus neoformans during Disseminated Murine
Cryptococcosis.
Schwarz P, Dromer F, Lortholary O, Dannaoui E.
Antimicrob Agents Chemother. 2006 Jan;50(1):113-20.
 Abstract

Comparison of in vitro Antifungal Activities of Amphotericin B Lipid Complex with
Itraconazole against 708 Clinical Yeast Isolates and Opportunistic Moulds Determined
by National Committee for Clinical Laboratory Standards Methods M27-A and M38-P.
Carrillo-Munoz AJ, Ruesga M, Brio S, Del Valle O, et al
 Chemotherapy 2002 Dec;48(5):224-231
 Abstract

Cryptococcosis in Australasia and the treatment of cryptococcal and other fungal i
nfections with liposomal amphotericin B.
Chen SC. 
J Antimicrob Chemother 2002 Jan;49 Suppl A:57-61
 Abstract

  
Fluconazole
       

        Journal Papers, Abstracts, and Commentaries

 
FULL TEXT ARTICLE
 Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or
400 mg/day of fluconazole
Schaars CF ,Meintjes GA,  Morron C, et al
BMC Infectious Diseases 2006, 6:118
 Paper
 
Symptomatic Relapse of HIV-Associated Cryptococcal Meningitis after Initial Fluconazole
Monotherapy: The Role of Fluconazole Resistance and Immune Reconstitution.
Bicanic T, Harrison T, Niepieklo A, et al
Clin Infect Dis. 2006 Oct 15;43(8):1069-73.
Abstract
 
Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical
outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole |
prophylaxis.
Manosuthi W, Sungkanuparph S, Thongyen S, et al  
J Med Assoc Thai. 2006 Jun;89(6):795-802
 Abstract
 
FULL TEXT PDF ARTICLE
 Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400
mg/day of fluconazole.
Schaars CF, Meintjes GA, Morroni C, et al 
BMC Infect Dis. 2006 Jul 18;6(1):118
Paper
 
FULL-TEXT PDF ARTICLE
 Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving
fluconazole for cryptococcal prophylaxis: a case-control study
 Manosuthi W, Chumpathat N, Chaovavanich A, Sungkanuparph S 
BMC Infectious Diseases 2005, 5:67
Paper
 
A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal
meningitis prophylaxis in HIV-infected patients with severe immune deficiency.
Chetchotisakd P, Sungkanuparph S, Thinkhamrop B, et al
HIV Med. 2004 May;5(3):140-3.
 Abstract

Successful discontinuation of fluconazole as secondary prophylaxis for
cryptococcosis in AIDS patients respoding to highly active antiretroviral therapy.
Sheng WH, Hung CC, Chen MY, et al. I
Int J STD AIDS 2002 Oct;13(10):702-5
 Abstract

  
Flucytosine
       

        Journal Papers, Abstracts, and Commentaries

 
Oral versus intravenous flucytosine in patients with HIV-associated cryptococcal meningitis.
Brouwer AE, van Kan HJ, Johnson E, et al
Antimicrob Agents Chemother. 2006 Dec 28;
Abstract
HAART/ART
       

        Journal Papers, Abstracts, and Commentaries

 
Indinavir-treated Cryptococcus neoformans promotes an efficient antifungal immune
response in immunosuppressed hosts.
Pericolini E, Cenci E, Monari C, et al  
Med Mycol. 2006 Mar;44(2):119-26.
 Abstract

Discontinuation of Maintenance Therapy for Cryptococcal Meningitis in Patients
with AIDS Treated with Highly Active Antiretroviral Therapy: An International
Observational Study.
Mussini C, Pezzotti P, Miro JM, et al 
Clin Infect Dis. 2004 Feb 15;38(4):565-571
 Abstract
IFN-gamma
       

        Journal Papers, Abstracts, and Commentaries

 
Recombinant Interferon- gamma 1b as Adjunctive Therapy for AIDS-Related Acute
Cryptococcal Meningitis.
Pappas PG, Bustamante B, Ticona E, et al 
J Infect Dis. 2004 Jun 15;189(12):2185-91.
 Abstract

Induction of Interleukin-12 and Gamma Interferon Requires Tumor Necrosis
Factor Alpha for Protective T1-Cell-Mediated Immunity to Pulmonary Cryptococcus
neoformans Infection.
Herring AC, Lee J, McDonald RA, Toews GB, Huffnagle GB.
Infect Immun 2002 Jun;70(6):2959-64
 Abstract
IL-12
       

        Journal Papers, Abstracts, and Commentaries

  Induction of Interleukin-12 and Gamma Interferon Requires Tumor Necrosis Factor
Alpha for Protective T1-Cell-Mediated Immunity to Pulmonary Cryptococcus neoformans
Infection.
Herring AC, Lee J, McDonald RA, Toews GB, Huffnagle GB.
Infect Immun 2002 Jun;70(6):2959-64
 Abstract
Isavuconazole
       

        Journal Papers, Abstracts, and Commentaries

  Evaluation of Etest Method for Determining Isavuconazole MICs Against Cryptococcus gattii a
nd Cryptococcus neoformans.
Thompson GR 3rd, Fothergill AW, Wiederhold NP, et al   
Antimicrob Agents Chemother. 2008 Jun 16.
Abstract		  
Itraconazole
       

        Journal Papers, Abstracts, and Commentaries

  Comparison of in vitro Antifungal Activities of Amphotericin B Lipid Complex with
Itraconazole against 708 Clinical Yeast Isolates and Opportunistic Moulds Determined
by National Committee for Clinical Laboratory Standards Methods M27-A and M38-P.
Carrillo-Munoz AJ, Ruesga M, Brio S, Del Valle O, et al
 Chemotherapy 2002 Dec;48(5):224-231
 Abstract		  
Posaconazole
       
        Journal Papers, Abstracts, and Commentaries
 
  Posaconazole and amphotericin B combination therapy against Cryptococcus
neoformans infection.
Barchiesi F, Spreghini E, Schimizzi AM, et al  
Antimicrob Agents Chemother. 2004 Sep;48(9):3312-6.
Abstract
Saquinavir
       
        Journal Papers, Abstracts, and Commentaries
 
  Interaction between saquinavir and antimycotic drugs on C. albicans and C.
neoformans strains.
Casolari C, Rossi T, Baggio G, Coppi A,
Pharmacol Res. 2004 Dec;50(6):605-10.
 Abstract
Voriconazole
       
        Journal Papers, Abstracts, and Commentaries
 
 
Voriconazole Inhibits Melanization in Cryptococcus neoformans.
Martinez LR, Ntiamoah P, Gácser A, et al 
Antimicrob Agents Chemother. 2007 Dec;51(12):4396-400.
 Abstract
 
Efficacy of voriconazole in a murine model of cryptococcal central nervous system
infection.
Serena C, Pastor FJ, Mariné M, et al
J Antimicrob Chemother. 2007 May 4;
Abstract

Voriconazole treatment for less-common, emerging, or refractory fungal infections.
Perfect JR, Marr KA, Walsh TJ,et al.
Clin Infect Dis 2003 May 1;36(9):1122-31
 Abstract

  
Azoles: General Reports
       
        Journal Papers, Abstracts, and Commentaries
 
  Prevention of cryptococcosis in HIV-infected patients with limited access to highly active
antiretroviral therapy: evidence for primary azole prophylaxis.
Caney P, Stephens D, Rimland D.
HIV Med. 2005 Jul;6(4):253-9
 Abstract		  
Antifungals: General Reports
       
        Journal Papers, Abstracts, and Commentaries
 
  Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV.
Chang L, Phipps W, Kennedy G, Rutherford G. 
Cochrane Database Syst Rev. 2005 Jul 20;(3):CD004773. 
Abstract		  
Antiretrovirals: General Reports
       
        Journal Papers, Abstracts, and Commentaries
 
  Impact of antiretroviral therapy on the relapse of cryptococcosis and survival of HIV-infected
Patients with cryptococcal infection.
Jongwutiwes U, Kiertiburanakul S, Sungkanuparph S.  
Curr HIV Res. 2007 May;5(3):355-60.
 Abstract		  

Cryptococcosis Main Page Main New/Noteworthy Home Page 

Cryptococcosis Drugs